On Wednesday, Shares of General Motors Company (NYSE:GM), gained 2.98% to $30.02.
General Motors Company and Navistar have reached a long-term agreement to develop and assemble future medium-duty, conventional cab Class 4/5 commercial vehicles, allowing Navistar to strengthen its product lineup and GM to expand its Chevrolet commercial truck portfolio.
“Bringing medium-duty conventional cab trucks back into the portfolio strengthens Chevrolet’s commitment to providing commercial customers with more choices and one-stop shopping for a versatile lineup of trucks, vans and crossovers,” said Ed Peper, U.S. vice president of GM Fleet and Commercial Sales.
The future products will be jointly developed using Navistar’s expertise in rolling chassis configurations and manufacturing capabilities, and GM’s commercial components and engines. The vehicles are slated for production in 2018 and will be manufactured at Navistar’s facility in Springfield, Ohio. Navistar plans to add 300 jobs and invest more than $12 million in facility upgrades and state-of-the-art equipment to produce the new vehicles.
General Motors Company (General Motors) designs, builds and sells cars, trucks and automobile parts across the world. The Company also provides automotive financing services through General Motors Financial Company, Inc. (GM Financial).
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), inclined 13.02% to $178.66, during its last trading session.
In an analyst report issued to investors and clients by BMO Capital Markets on Tuesday morning, Valeant Pharmaceuticals Intl (VRX) had its price target downgraded to $285.00. The firm right now has “Outperform” rating on the stock.
According to data compiled by Thomson Reuters, Valeant Pharmaceuticals Intl (NYSE:VRX)’s stock is covered by 4 equity analysts across the Street, with 1 analysts giving it a Sell rating, 17 a Buy rating, while 2 consider it a Hold. The 12-month consensus target price for the stock is $52.38, which reflects an downside potential of 67.48% over the current price.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Shares of Endo International (NASDAQ:ENDP), inclined 14.38% to $69.28, during its last trading session.
Endo International declared it has accomplished its formerly declared $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc. from leading global private investment firm TPG.
Through this acquisition, Endo has further established its position as a leading global specialty pharmaceutical company with a fast growing generics business that is among the top five as measured by U.S. sales according to IMS. The acquisition also assists position Endo for long-term double-digit organic growth, improved cash flow generation and raised financial flexibility. Endo’s generics portfolio now comprises an extensive range of in market and R&D stage complex and competitively differentiated dosage forms and delivery systems, with a focus on higher barrier-to-entry and first-to-market products. Endo’s combined U.S. Generics segment, which comprises Par Pharmaceutical and Qualitest, will be named Par Pharmaceutical, an Endo International Company and will be led by Paul Campanelli, former Chief Executive Officer of Par Pharmaceutical, who will also join Endo’s Executive Leadership Team.
“We are happy to declare the completion of this transformational acquisition that has plannedally expanded our product portfolio, R&D pipeline, manufacturing and technology capacity and generics expertise for the benefit of patients, customers and shareholders,” said Rajiv De Silva, President and CEO of Endo. “We are also happy to welcome Paul Campanelli, former CEO of Par Pharmaceutical, as Group President, Par Pharmaceutical to the Endo Executive Leadership Team and are excited about his anticipated contributions to the organization. I would like to take the opportunity to thank the leadership team and the hard working employees at Qualitest for ongoing to drive the business forward and deliver year-over-year double-digit growth during this period of transition. We look forward to the opportunities ahead for our combined generics business.”
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals.
Finally, Autodesk, Inc. (NASDAQ:ADSK), ended its last trade with -2.43% loss, and closed at $44.14.
Autodesk and CGarchitect, a leading online magazine and end-user community for visualization and design professionals, declared this year’s winners of the 2015 Autodesk Excellence in Infrastructure Competition to spotlight some of the world’s best applications of Building Information Modeling [BIM] for civil infrastructure projects.
In its fourth year, the Competition honors Arup, Ramboll - Parsons Brinckerhoff Joint Venture, and HNTB as the Competition’s first, second and third place winners for their transit and bridge projects. The competition also recognizes CivilE, LLC as small project award winner, and Dawn Digital Pvt. Ltd. as the visualization award winner.
“Each of the winning projects offers a model for the application of forward-thinking Building Information Modeling workflows and technologies for challenging infrastructure projects,” said Amar Hanspal, senior vice president, Autodesk. “First place Arup, for example, created a large-scale model for a section of a 17 km-long railway line that integrates GIS data from multiple sources and formats and merged this information with the projected station, tunnels, public facilities and as-built records of the adjacent buildings. This remarkable effort demonstrated how the application of BIM process-based technologies and practices can assist manage project scope and foster cross-disciplinary design to support design reviews, improve constructability, manage traffic and communicate more effectively with all stakeholders.”
Autodesk, Inc. (Autodesk) is a design software and services company, offering customers productive business solutions through technology products and services. The Company serves customers in the architecture, engineering and construction; manufacturing, and digital media, consumer and entertainment industries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
